PHYSICAL CHEMISTRY OF THERAPEUTIC PLASMA PROTEINS

治疗性血浆蛋白的物理化学

基本信息

  • 批准号:
    3336613
  • 负责人:
  • 金额:
    $ 18.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1978
  • 资助国家:
    美国
  • 起止时间:
    1978-01-01 至 1986-08-31
  • 项目状态:
    已结题

项目摘要

This proposal describes research into the physicochemical properties of selected plasma proteins including antithrombin III, Cl-inactivator, alpha2-plasmin inhibitor, and fibronectin, all of which have potential value for replacement therapy in patients with either inherited or acquired deficiences. The program will expedite the development of new or improved methods of isolating and preserving these proteins in a form suitable for clinical evaluation. The solubility of various proteins will be evaluated in the presence of polyethylene glycol, an inert fractional precipitating agent, which is being developed as an alternative to ethanol for large-scale fractionation. We will seek ways of selectively manipulating the solubility of specific proteins, for example by addition of substances with which they preferentially interact. Secondly, these proteins will be examined with respect to their stability towards various forms of stress, with particular emphasis on thermal stability, the objective being to define conditions under which they can be pasteurized to diminish the risk of transfusion hepatitis. Finally, we propose to develop a broad program of investigation of protein-protein and protein-ligand interactions in human plasma, with emphasis on the use of fluorescence spectroscopy and high pressure liquid chromatography. Systems to be investigated include: (1) the interaction of the above three protease inhibitors with the relevant proteases and zymogens, (2) the interaction of fibronectin with fibrin(ogen), collagen, and heparin, (3) the interaction between various fragments of these proteins. The results of these studies, in addition to clarifying structure/function relationships, will be applied to the development of fluorescent binding assays and improved purification schemes based on affinity principles.
这一建议描述了对选定的物理化学性质的研究

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH C. INGHAM其他文献

KENNETH C. INGHAM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH C. INGHAM', 18)}}的其他基金

Core--Macromolecular analysis and interactions
核心--大分子分析与相互作用
  • 批准号:
    6644330
  • 财政年份:
    2002
  • 资助金额:
    $ 18.72万
  • 项目类别:
SHARED CIRCULAR DICHROMETER/FLUOROMETER
共享圆形二色计/荧光计
  • 批准号:
    6291973
  • 财政年份:
    2001
  • 资助金额:
    $ 18.72万
  • 项目类别:
Core--Macromolecular analysis and interactions
核心--大分子分析与相互作用
  • 批准号:
    6504144
  • 财政年份:
    1996
  • 资助金额:
    $ 18.72万
  • 项目类别:
DOMAIN STRUCTURE OF PLATELET INTEGRIN IIB-IIIA
血小板整合素 IIB-IIIA 的结构域
  • 批准号:
    3432702
  • 财政年份:
    1993
  • 资助金额:
    $ 18.72万
  • 项目类别:
DOMAIN STRUCTURE OF PLATELET INTEGRIN IIB-IIIA
血小板整合素 IIB-IIIA 的结构域
  • 批准号:
    2291749
  • 财政年份:
    1993
  • 资助金额:
    $ 18.72万
  • 项目类别:
DOMAIN STRUCTURE OF PLATELET INTEGRIN IIB-IIIA
血小板整合素 IIB-IIIA 的结构域
  • 批准号:
    2291750
  • 财政年份:
    1993
  • 资助金额:
    $ 18.72万
  • 项目类别:
NHLBI SHARED RESEARCH FACILITY FOR MOLECULAR BIOLOGY
NHLBI 分子生物学共享研究设施
  • 批准号:
    3003479
  • 财政年份:
    1987
  • 资助金额:
    $ 18.72万
  • 项目类别:
INTERACTIONS OF FIBRONECTIN MODULES
纤连蛋白模块的相互作用
  • 批准号:
    2685278
  • 财政年份:
    1978
  • 资助金额:
    $ 18.72万
  • 项目类别:
PHYSICAL CHEMISTRY OF THERAPEUTIC PLASMA PROTEINS
治疗性血浆蛋白的物理化学
  • 批准号:
    3336616
  • 财政年份:
    1978
  • 资助金额:
    $ 18.72万
  • 项目类别:
PHYSICAL CHEMISTRY OF THERAPEUTIC PLASMA PROTEINS
治疗性血浆蛋白的物理化学
  • 批准号:
    3336615
  • 财政年份:
    1978
  • 资助金额:
    $ 18.72万
  • 项目类别:

相似海外基金

EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
  • 批准号:
    479295
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
  • 批准号:
    10629057
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
  • 批准号:
    23K06906
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
  • 批准号:
    10605482
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
  • 批准号:
    10559071
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
  • 批准号:
    22K07388
  • 财政年份:
    2022
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
  • 批准号:
    10536789
  • 财政年份:
    2022
  • 资助金额:
    $ 18.72万
  • 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
  • 批准号:
    22K06743
  • 财政年份:
    2022
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
  • 批准号:
    461790
  • 财政年份:
    2022
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
  • 批准号:
    474475
  • 财政年份:
    2022
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了